Abstract
Chemotherapy-induced nausea and vomiting (CINV) is among the most common side-effects reported by cancer patients undergoing chemotherapy. This analysis aimed to evaluate the cost-effectiveness of fixed-combination netupitant/palonosetron (NEPA) compared with other commonly used antiemetic treatments for the prevention of CINV in patients undergoing highly emetogenic chemotherapy (HEC) in the UK.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
